Table 1.
A summary of all CRC-related RBPs reviewed in this work: miRNAs control and their clinical relevance.
| RBP | Control by miRNAs | Clinical relevance |
|---|---|---|
| LIN28 | miR-let-7, miR-26a, miR-181, miR-9, miR-30, miR-125, miR-212 and miR-27 | - Aberrant expression correlates with reduced patient survival. - Predictive biomarker for chemotherapy. |
| MSI | miR-137 | - High expression correlates with increased metastatic risk and poorer survival. - Promotes resistance to 5-FU. |
| ELAVL1 | miR-519 and miR-22 | - High expression correlates with malignancy and multidrug resistance. |
| QKI | miR-574-5p and miR-155 | - Low expression correlates with poorer prognosis. - Could predict recurrence and prognosis. |
| RBM3 | - Promotes resistance to chemotherapy | |
| CELF1 | miR-503 | |
| IGF2BPs | - Overexpression correlates to unfavorable clinical outcomes: early dissemination, poor response to the therapy, increased tumor aggressiveness, and short survival. | |
| ESRP1 | - Overexpression associates with a favorable overall survival outcome. | |
| TTP | miR-29a | - Downregulation correlates with poor prognosis, tumor aggressiveness, and necrosis. |
| hnRNPs | - Poor prognosis marker. | |
| TIA1 | miR-19a | - Increased numbers of TIA-1 positive TILs is associated with an improved clinical outcome. - TIA1 can also be used to supplement prognostic information related to TNM stage and adjuvant therapy. |
| KHDRBS1 | - KHDRBS1 nuclear localization and overexpression is correlated with poor tumor differentiation, advanced T stage, lymph node involvement, and distant metastasis. | |
| CPEB4 | miR-203 | - Overexpression correlates with tumor progression and poor overall survival. |
| CSDE1 | - Overexpression is associated to poor prognosis. |